Efficacy and safety of sovleplenib (HMPL-523) in adult patients with chronic primary immune thrombocytopenia in China (ESLIM-01): a randomised, double-blind, placebo-controlled, phase 3 study

作者：Yu Hu, Xiaofan Liu, Hu Zhou, Shujie Wang, Ruibin Huang, Yi Wang, Xin Du, Jing Sun, Zeping Zhou, Zhenyu Yan, Wen-Ming Chen, Wei Wang, Qingchi Liu, Qingshu Zeng, Yuping Gong, Jie Yin, Xuliang Shen, Baodong Ye, Yun Chen, Yajing Xu, Huiping Sun, Yunfeng Cheng, Zhuogang Liu, Chunling Wang, Guolin Yuan, Xiaohui Zhang, Xin Li, Cheng Peng, Xinhong Guo, Zhongxing Jiang, Feng'e Yang, Linhua Yang, Chengwei Luo, Taiwu Xiao, Sisi Fu, Hongyan Yin, Xiaojun Guo, Qian Xu, Songhua Fan, Michael Shi, Weiguo Su, Heng Mei, Renchi Yang · 发表于：The Lancet Haematology · 年份：2024 · DOI：10.1016/s2352-3026(24)00139-x · 被引用次数：29 · 研究领域：Platelet Disorders and Treatments、Mast cells and histamine、Heparin-Induced Thrombocytopenia and Thrombosis